Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Fulgent Genetics, Inc. (FLGT) is a Medical - Diagnostics & Research company based in US with a market capitalization of $528.9M. Revenue grew 13.8% year-over-year and free cash flow was negative at -$124.2M. This page tracks FLGT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 1.31K employees · IPO Sep 29, 2016
Valuation
Valuation & price
$15.70as of May 17, 2026· -49.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.48
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$528.9M
Market cap
13.8%
Revenue growth (YoY)
40.6%
Gross margin
-$124.2M
Free cash flow (USD)
-$328.4M
Net debt
Net cash position
1.8%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
4
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 1, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJun 3, 2026Filing
Insider Sell $30KGao Hanlin · Chief Scientific Officer · $30.2K
- Insider sellJun 3, 2026Filing
Insider Sell $38KXie Jian · President and COO · $38.4K
- 8-K eventJun 2, 2026Filing
Data Presentation at ASCO
- Insider sellMay 28, 2026Filing
Insider Sell $17KGao Hanlin · Chief Scientific Officer · $16.6K
- Insider sellMay 28, 2026Filing
Insider Sell $21KXie Jian · President and COO · $21.1K
- 8-K eventMay 21, 2026Filing
Abstract Publication
- 8-K eventMay 14, 2026Filing
Equity Incentive Plan
- 8-K eventMay 1, 2026Filing
Earnings Release
- Quarterly reportMay 1, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Fulgent Genetics, Inc.'s market cap?
Fulgent Genetics, Inc. (FLGT) has a market capitalization of $528.9M.
What is FLGT's P/E ratio?
A meaningful P/E ratio is not available for FLGT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is FLGT's price-to-book (P/B) ratio?
FLGT trades at 0.48 times book value per share.
Are insiders buying FLGT stock?
SEC Form 4 filings show no open-market insider buys at Fulgent Genetics, Inc. in the last 90 days (4 sells).
Same arena
Related companies in Medical - Diagnostics & Research
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.